新诊断或复发前列腺癌患者中18F-氟妥昔司他图像判读的阅片者间与阅片者内可重复性:两项3期前瞻性多中心研究数据
基于两项3期前瞻性多中心研究的掩蔽图像评估,评估新诊断(n=352)或复发(n=389)前列腺癌患者18F-氟妥昔司他PET/CT的阅片者间与阅片者内可重复性。3名掩蔽阅片者判读,配对阅片者间一致率新诊断组≥95%、复发组≥75%,Fleiss κ分别为0.50和0.41,阅片者内一致率两组均≥86%。结论认为该图像可可靠判读,具有高度阅片者间和阅片者内一致性。
要点
- 新诊断患者配对阅片者间一致率≥95%,复发患者≥75%。
- Fleiss κ在新诊断患者为0.50,复发患者为0.41。
- 两组阅片者内一致率均≥86%。
核心结论
- 18F-氟妥昔司他PET/CT图像可可靠判读,具有高度阅片者间和阅片者内一致性。
研究设计与样本
- 两项3期前瞻性多中心研究,对新诊断(n=352)或复发(n=389)前列腺癌患者的18F-氟妥昔司他PET/CT图像进行掩蔽评估,由3名掩蔽阅片者判读。
主要发现
- 配对阅片者间一致率在新诊断患者为95%或更好,在复发患者为75%或更好。
- Cohen κ从不可估计至0.55,Fleiss κ在新诊断患者为0.50、复发患者为0.41。
- 一致率在新诊断患者前列腺部位最高(≥95%),在复发患者盆腔淋巴结最高(≥87%)。
- 阅片者内一致率(首次与重复判读,20%图像,≥4周后)在两组均≥86%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interreader and intrareader reproducibility of 18F-flotufolastat PET/CT scans in newly diagnosed and recurrent prostate cancer patients was assessed from masked image evaluations from two phase 3 studies. Methods: 18F-flotufolastat PET/CT images of newly diagnosed (n = 352) or recurrent (n = 389) patients were evaluated by 3 masked readers. Cohen κ was used to assess pairwise patient- and region-level interreader agreement. Agreement among all readers was assessed using Fleiss κ. Intrareader agreement between the first and repeat read (20% of images, ≥4 wk later) was assessed using Cohen κ. Results: Pairwise interreader agreement was 95% or better (newly diagnosed) and 75% or better (recurrent). The κ coefficients were impacted by the high-agreement-low-κ paradox: Cohen κ ranged from not estimable to 0.55, whereas Fleiss κ was 0.50 (newly diagnosed) and 0.41 (recurrent). Agreement was highest in the prostate of newly diagnosed patients (≥95%) and in the pelvic lymph nodes in recurrent patients (≥87%). Intrareader agreement was 86% or better across both populations. Conclusion: 18F-flotufolastat PET/CT images can be reliably interpreted, with a high degree of inter- and intrareader agreement.
引用
- Kuo PH, Esposito G, Ulaner GA, et al. Interreader and Intrareader Reproducibility of 18F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies. J Nucl Med. 2024. PMID: 38871390. doi:10.2967/jnumed.123.267306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。